# Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

> **NCT07276373** · PHASE1,PHASE2 · RECRUITING · sponsor: **Corcept Therapeutics** · enrollment: 50 (estimated)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Nenocorilant 200 mg
- **DRUG:** Nenocorilant 300 mg
- **DRUG:** Nenocorilant 400 mg
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT07276373
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-16
- **Primary completion:** 2026-09
- **Final completion:** 2027-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07276373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07276373, "Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07276373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*